Lifileucel: FDA-approved T-cell therapy for melanoma

被引：3

作者：

Kwong, Mei Li M. ^{[1
]}

Yang, James C. ^{[1
]}

机构：

[1] NCI, Surg Branch, NIH, Bethesda, MD 20814 USA

来源：

ONCOLOGIST | 2024年 / 29卷 / 08期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC MELANOMA; ADOPTIVE TRANSFER; IMMUNOTHERAPY; INTERLEUKIN-2; EFFICACY; CANCER;

D O I：

10.1093/oncolo/oyae136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This commentary reports on the history of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy and where TIL fits into the treatment options for metastatic melanoma.

引用

页码：648 / 650

页数：3

共 50 条

[41] The First FDA-Approved Batches of Botox®
Johnson, Eric A.
TOXICON, 2022, 214 : S28 - S28
[42] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (06) : 544 - 544
[43] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (01) : 33 - 33
[44] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (15) : 1537 - 1537
[45] FDA-approved drug promotes remyelination
Sarah Lempriere
Nature Reviews Neurology, 2022, 18 : 637 - 637
[46] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (18) : 1714 - 1714
[47] Trends in FDA-Approved Cancer Therapies
Hilas, Olga
US PHARMACIST, 2023, 48 (10) : 14 - 14
[48] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (22) : 2294 - 2294
[49] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (10) : 1004 - 1004
[50] NIH Support for FDA-Approved Medicines
Griesenauer, Rebekah H.
Moore, Ryan
Kinch, Michael S.
CELL CHEMICAL BIOLOGY, 2017, 24 (11): : 1315 - 1316

← 1 2 3 4 5 →